<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Arthritis Res. Ther</journal-id><journal-title-group><journal-title>Arthritis Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3891298</article-id><article-id pub-id-type="publisher-id">ar4220</article-id><article-id pub-id-type="doi">10.1186/ar4220</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Abstract</subject></subj-group></article-categories><title-group><article-title>Historical overview</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Calabrese</surname><given-names>Leonard H</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Professor of Medicine, Cleveland Clinic Lerner College of Medicine, RJ Fasenmyer Chair of Clinical Immunology, Cleveland Clinic Foundation, Cleveland, Ohio, USA</aff><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>11</day><month>7</month><year>2013</year></pub-date><volume>15</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">Treatment of SLE: bridging the gap from clinical trials to the clinic</named-content></supplement><fpage>A2</fpage><lpage>A2</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 Calabrese; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Calabrese; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://arthritis-research.com/content/15/S2/S2"/><conference><conf-date><day>11</day><month>11</month><year>2012</year></conf-date><conf-name>Treatment of SLE: bridging the gap from clinical trials to the clinic</conf-name><conf-loc>Washington, DC, USA</conf-loc></conference></article-meta></front><body><sec><title/><p>Medical understanding systemic lupus erythematosus (SLE) has evolved dramatically since its first reference during the 1100s, through the neoclassic period of the 1800s when researchers began to refine the definition, and into the modern era with transformative laboratory investigations and discoveries altering the diagnosis and treatment. Weaved into this historic overview are descriptions of the most important contributions of the leading practitioners and researchers.</p><p>Additional file <xref ref-type="supplementary-material" rid="S1">1</xref> contains an edited transcript of the full presentation.</p></sec><sec><title>Competing interests</title><p>LHC has received consulting fees from Amgen, BMS, Centecor, Genentech/Roche, Pfizer, Sanofi Aventis and Savient.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title></caption><media xlink:href="ar4220-S1.pdf"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body></article>